ISARIC provides a collaborative platform through which global, patient‐oriented clinical studies can be developed, executed and shared.
Protocols addressing the most important questions between and during epidemics of severe acute respiratory infections and other rapidly emerging public health threats are undertaken in order to generate new knowledge, maximise the availability of clinical information, and thereby save lives.
Healthcare professionals in COVID-19 hospital (Photo credit: Professor Bin Cao, China-Japan Friendship Hospital, China)
International Severe Acute Respiratory and emerging Infection Consortium
What we do
Our purpose is to prevent illness and deaths from infectious disease outbreaks.
We are a global federation of clinical research networks, providing a proficient, coordinated, and agile research response to outbreak-prone infectious diseases.
COVID-19 resources:
In December 2019, a novel coronavirus (SARS-CoV-2) emerged to cause a pandemic of a severe coronavirus disease (COVID-19). ISARIC has created tools for investigators to collect and store data in a standardised way and has supported clinical trials of treatments.
Publication library
See below our featured research areas:
COVID-19 CCP
COVID-19
Follow-up study
Lassa fever
Ebola
Data Tools
If you want to use these research tools or if you require further information, please contact the ISARIC team: gsc@isaric.org
Latest news
ISARIC COVID-19 clinical database passes the half million patient records mark
On its 10th anniversary, University of Oxford’s ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium) demonstrates the crucial role of global preparedness and collaboration for advancing knowledge on infectious disease pandemics.
Children older than 6 and with reported allergic diseases are at greater risk of Long COVID, paediatric study finds
Researchers from ISARIC (International Severe Acute Respiratory and emerging Infection Consortium) paediatric Long Covid working group in the UK, Sechenov University and Z.A. Bashlyaeva Children’s Municipal Clinical Hospital in Russia ran the largest study to date on children hospitalised with COVID 19.
Time to reconsider the role of ribavirin in Lassa fever
Ribavirin is the only available Lassa fever–specific treatment and has been used routinely for over 25 years. However, ribavirin is not licensed for Lassa fever, its mechanism of action is unclear, it is expensive and hard to source, and it has well-known toxicities.
Events
Use of convalescent plasma in patients hospitalised with COVID-19
Event date - 10/06/2021
Plasma from patients who have recovered from SARS-CoV-2 infection (convalescent plasma) contains antibodies that can bind to and neutralise the virus.
Non-invasive ventilation strategies in COVID-19 – sharing experiences
Event date - 17/12/2020
This forum aims to review evidence and strategies for Non-invasive ventilation (NIV) in COVID, develop and promote research ideas and evidence-based practice.
Long COVID Forum: 9-10 December 2020
Event date - 09/12/2020
Currently very little is known about the clinical, biological, psychological and socio-environmental impact of Coronavirus Disease 2019 (COVID-19). While most people have uncomplicated recoveries, some continue to live with prolonged illness and symptoms.